Cancer surveillance based on imaging techniques in carriers of<i>BRCA1</i>/<i>2</i>gene mutations: a systematic review

Bermejo-Perez, MJ; Márquez-Calderón, Soledad; Llanos-Méndez, Aurora

doi:10.1259/bjr/21074350

Cited by 15 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intensive screening is reportedly tolerated and preferred by women at high risk over options such as prophylactic mastectomy [25,26]. Trials are ongoing to optimize breast cancer surveillance strategies for carriers of BRCA1/2 mutations or women who are otherwise at high risk for developing breast cancer [27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population

et al. 2010

View full text Add to dashboard Cite

Low breast cancer screening rates are often found among ethnic minority groups and those born outside the host country. This is of particular concern for high-risk groups, who should benefit from ongoing trials aimed at optimizing screening strategies for breast, as well as ovarian cancer. Both of these issues are germane for Jewish women in Europe. We systematically review the literature concerning breast cancer early detection practices (BCEDP) among Jewish women, and examine European surveillance studies of high-risk for breast and/or ovarian cancer that had imaging in the surveillance protocol, in order to assess the likelihood of adequately including women from minority ethnic groups. No studies were found about BCEDP among Jewish women in Europe. Twenty-one research groups from Israel or the US addressed BCEDP among Jewish women. Some Jewish women in the US and Israel, including recent immigrants, are under-screened. Twenty-four research groups reported imaging surveillance of women at increased risk for breast and/or ovarian cancer in Europe. There was a clear benefit to magnetic resonance imaging and/or more intensive screening for women with increased breast cancer risk. Some of these surveillance studies considered ethnic minority groups at high risk, including Jewish women, but none provided adequate outreach to ensure that these groups were included in their programs. The specific screening needs of Jewish and other high-risk ethnic minority groups in Europe have not been met regarding breast and ovarian cancer. A European-wide, population-based approach is suggested, with cultural sensitivity being vital for these efforts.

show abstract

Section: Introductionmentioning

confidence: 99%

Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Intensive screening using various imaging modalities is reportedly tolerated and preferred by women at high risk, compared to options such as prophylactic mastectomy (9,10). Many investigations have focused upon finding the best strategies for screening surveillance of women with high breast cancer risk (11,12). In the Uk women at very high risk of familial breast cancer are being offered annual surveillance with magnetic resonance imaging from age 30 to 49 years and annual mammography from the age of 40-69 (13).…”

Section: Breast Cancer Survival Disparities Ethnicity and Related Ismentioning

confidence: 99%

Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review)

Belkić

Cohen

Wilczek

et al. 2015

International Journal of Oncology

View full text Add to dashboard Cite

Abstract. Women from ethnic minority groups, including immigrants and refugees are reported to have low breast cancer (BC) screening rates. Active, culturally-sensitive outreach is vital for increasing participation of these women in BC screening programs. Women at high BC risk and who belong to an ethnic minority group are of special concern. Such women could benefit from ongoing trials aimed at optimizing screening strategies for early BC detection among those at increased BC risk. Considering the marked disparities in BC survival in Europe and its enormous and dynamic ethnic diversity, these issues are extremely timely for Europe. We systematically reviewed the literature concerning European surveillance studies that had imaging in the protocol and that targeted women at high BC risk. The aim of the present review was thereby to assess the likelihood that women at high BC risk from minority ethnic groups were adequately included in these surveillance programs. Twenty-seven research groups in Europe reported on their imaging surveillance programs for women at increased BC risk. The benefit of strategies such as inclusion of magnetic resonance imaging and/or more intensive screening was clearly documented for the participating women at increased BC risk. However, none of the reports indicated that sufficient outreach was performed to ensure that women at increased BC risk from minority ethnic groups were adequately included in these surveillance programs. On the basis of this systematic review, we conclude that the specific screening needs of ethnic minority women at increased BC risk have not yet been met in Europe. Active, culturally-sensitive outreach is needed to identify minority women at increased BC risk and to facilitate their inclusion in on-going surveillance programs. It is anticipated that these efforts would be most effective if coordinated with the development of European-wide, population-based approaches to BC screening. Contents

show abstract

“…Different options for risk management of hereditary ovarian cancer are available, i.e., surveillance, prophylactic surgeries, and chemoprevention [47].…”

Section: The Risk Management Of Hocmentioning

confidence: 99%

“…Assessments of lifetime ovarian cancer risk for women who carry the mutations are still being defined: currently, they range from 16% to 60% for BRCA1 and 10-27% for BRCA2 [29,43,47].…”

Section: The Risk Management Of Hocmentioning

confidence: 99%

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

Tinelli

Malvasi

Leo

et al. 2010

Cancer Metastasis Rev

View full text Add to dashboard Cite

In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.

show abstract

Cancer surveillance based on imaging techniques in carriers ofBRCA1/2gene mutations: a systematic review

Cited by 15 publications

References 32 publications

Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population

Screening of high-risk groups for breast and ovarian cancer in Europe: a focus on the Jewish population

Imaging surveillance programs for women at high breast cancer risk in Europe: Are women from ethnic minority groups adequately included? (Review)

Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal

Contact Info

Product

Resources

About